Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 19/20 | 0.58 |
| ▸ | MMP13 | P45452 | 16/20 | 0.52 |
| ▸ | MMP2 | P08253 | 7/20 | 0.52 |
| ▸ | MMP9 | P14780 | 6/20 | 0.52 |
| ▸ | MMP3 | P08254 | 5/20 | 0.52 |
| ▸ | MMP8 | P22894 | 5/20 | 0.52 |
| ▸ | MMP14 | P50281 | 7/20 | 0.48 |
| ▸ | MMP7 | P09237 | 2/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | MMP10 | P09238 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3921083 | 0.93 | MMP1 (0.55) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6813262 | 0.92 | MMP1 (0.67) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6813516 | 0.92 | MMP1 (0.54) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6693057 | 0.92 | MMP1 (0.68) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6873149 | 0.90 | MMP1 (0.70) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7347709 | 0.85 | MMP1 (0.56) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7352211 | 0.85 | MMP1 (0.45) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL3914707 | 0.84 | MMP1 (0.63) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL13898990 | 0.84 | MMP1 (0.58) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL3987272 | 0.84 | MMP1 (0.68) | MMP1MMP13MMP2MMP9MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1415984-A1 | Aryloxyarylsulfonylamino hydroxamic acid derivatives | Pfizer Products Inc. (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6417229-B1 | ENZYME INHIBITORS | PFIZER INC | 2002-07-09 | — | — | US | disclosed |
| EP-1088550-A1 | alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| EP-1003720-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007675-A1 | ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-02-18 | — | — | WO | disclosed |